There has been recent reports in newspapers quoting IQVIA data about the de-growth in pharma market. Alembic Pharmaceuticals Ltd has clarified in this regard.
Indian Pharmaceutical Market ("IPM") for April 22 & May 22 has shown de-growth of -9% & -6%. Whereas, Alembic Pharmaceuticals Limited ("Alembic") has shown a de-growth of -8% & -12% respectively due to Anti-infective segment having higher base in April 21 & May 21 (Second Covid wave effect) which got normalized in current year April 22 and May 22.
Alembic's Branded Business Ex-Azithromycin has shown growth of +8% & +14% in April 22 & May 22 respectively (v/s IPM de-growth of -9% and -5% ex of Azithromycin)
Alembic's speciality segments continue to show a robust momentum on the back enhanced operational momentum and strong new product launches.
Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 727.20 as compared to the previous close of Rs. 709.40. The total number of shares traded during the day was 8513 in over 695 trades.
The stock hit an intraday high of Rs. 732.55 and intraday low of 690.50. The net turnover during the day was Rs. 6163480.00.
